Barclays PLC Bei Gene, Ltd. Call Options Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$143.93 - $224.51 $3.89 Million - $6.06 Million
27,000 Added 90.0%
57,000 $12.8 Million
Q2 2024

Aug 14, 2024
BUY
$129.52 - $174.32 $3.89 Million - $5.23 Million
30,000 New
30,000 $4.28 Million
Q4 2023

Feb 15, 2024
BUY
$158.67 - $201.58 $2.38 Million - $3.02 Million
15,000 New
15,000 $2.71 Million
Q3 2018

Nov 14, 2018
BUY
$152.62 - $189.66 $1.31 Million - $1.63 Million
8,600 New
8,600 $1.48 Million

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email